Design of the Rivaroxaban for Heparin-induced Thrombocytopenia Study

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2014 Feb 20

PMID 24549975

Citations 8

Authors

Lori-Ann Linkins

Theodore E Warkentin

Menaka Pai

Sudeep Shivakumar

Rizwan A Manji

Philip S Wells

Mark A Crowther

Affiliations

Soon will be listed here.

Abstract

Rivaroxaban is an ideal potential candidate for treatment of heparin-induced thrombocytopenia (HIT) because it is administered orally by fixed dosing, requires no laboratory monitoring and is effective in the treatment of venous and arterial thromboembolism in other settings. The Rivaroxaban for HIT study is a prospective, multicentre, single-arm, cohort study evaluating the incidence of new symptomatic venous and arterial thromboembolism in patients with suspected or confirmed HIT who are treated with rivaroxaban. Methodological challenges faced in the design of this study include heterogeneity of the patient population, differences in the baseline risk of thrombosis and bleeding dependent on whether HIT is confirmed or just suspected, and heterogeneity in laboratory confirmation of HIT. The rationale for how these challenges were addressed and the final design of the Rivaroxaban for HIT study is reviewed.

Citing Articles

Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature.

Ezekwudo D, Chacko R, Gbadamosi B, Batool S, Gaikazian S, Warkentin T Exp Hematol Oncol. 2017; 6:21.

PMID: 28725494 PMC: 5513338. DOI: 10.1186/s40164-017-0080-7.

Dabigatran approaching the realm of heparin-induced thrombocytopenia.

Ho P, Siordia J Blood Res. 2016; 51(2):77-87.

PMID: 27382551 PMC: 4931941. DOI: 10.5045/br.2016.51.2.77.

Novel oral anticoagulants for heparin-induced thrombocytopenia.

Skelley J, Kyle J, Roberts R J Thromb Thrombolysis. 2016; 42(2):172-8.

PMID: 27102287 DOI: 10.1007/s11239-016-1365-0.

Effect of Heparin on Coagulation Tests: A Comparison of Continuous and Bolus Infusion in Haemodialysis Patients.

Nasiri A, Ahmadidarrehsima S, Balouchi A, Shahdadi H, Moghadam M J Clin Diagn Res. 2016; 10(2):OC18-21.

PMID: 27042496 PMC: 4800562. DOI: 10.7860/JCDR/2016/18476.7231.

Successful Treatment of Dual-Positive Anti-Myeloperoxidase and Anti-Glomerular Basement Membrane Antibody Vasculitis with Pulmonary-Renal Syndrome.

Huang J, Wu L, Huang X, Xie Y, Yu J, Yang J Case Rep Nephrol Dial. 2016; 6(1):1-7.

PMID: 26889474 PMC: 4748756. DOI: 10.1159/000443163.

References

Warkentin T, Pai M, Sheppard J, Schulman S, Spyropoulos A, Eikelboom J . Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011; 9(12):2389-96. DOI: 10.1111/j.1538-7836.2011.04487.x. View

Boyce S . Challenges to the design and execution of controlled clinical studies of anticoagulants in patients with heparin-induced thrombocytopenia: lessons learned. J Thromb Thrombolysis. 2011; 33(1):124-8. DOI: 10.1007/s11239-011-0634-1. View

Linkins L, Warkentin T . Heparin-induced thrombocytopenia: real-world issues. Semin Thromb Hemost. 2011; 37(6):653-63. DOI: 10.1055/s-0031-1291375. View

Krauel K, Hackbarth C, Furll B, Greinacher A . Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2011; 119(5):1248-55. DOI: 10.1182/blood-2011-05-353391. View

Cuker A . Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost. 2011; 106(6):993-4. DOI: 10.1160/TH11-09-0677. View

Warkentin T, Kelton J . A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996; 101(5):502-7. DOI: 10.1016/s0002-9343(96)00258-6. View

WALLIS D, Workman D, Lewis B, Steen L, Pifarre R, MORAN J . Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999; 106(6):629-35. DOI: 10.1016/s0002-9343(99)00124-2. View

Donat F, Duret J, Santoni A, Cariou R, Necciari J, Magnani H . The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002; 41 Suppl 2:1-9. DOI: 10.2165/00003088-200241002-00001. View

Linkins L, Dans A, Moores L, Bona R, Davidson B, Schulman S . Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e495S-e530S. PMC: 3278058. DOI: 10.1378/chest.11-2303. View

10.

Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin T . Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011; 364(14):1305-14. DOI: 10.1056/NEJMoa1014475. View

11.

Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G . Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005; 78(4):412-21. DOI: 10.1016/j.clpt.2005.06.011. View

12.

Price E, Hayward C, Moffat K, Moore J, Warkentin T, Zehnder J . Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost. 2007; 98(6):1357-61. DOI: 10.1160/th07-06-0401. View

13.

Lo G, Juhl D, Warkentin T, Sigouin C, Eichler P, Greinacher A . Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4(4):759-65. DOI: 10.1111/j.1538-7836.2006.01787.x. View

14.

Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, Gallus A . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. DOI: 10.1056/NEJMoa1007903. View

15.

Warkentin T, Greinacher A, Koster A, Lincoff A . Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):340S-380S. DOI: 10.1378/chest.08-0677. View

16.

Sheridan D, Carter C, Kelton J . A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986; 67(1):27-30. View

17.

Schwann T, Kistler L, Engoren M, Habib R . Incidence and predictors of postoperative deep vein thrombosis in cardiac surgery in the era of aggressive thromboprophylaxis. Ann Thorac Surg. 2010; 90(3):760-6. DOI: 10.1016/j.athoracsur.2010.03.117. View

18.

Warkentin T, Chong B, Greinacher A . Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998; 79(1):1-7. View

19.

Warkentin T . How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program. 2011; 2011:143-9. DOI: 10.1182/asheducation-2011.1.143. View

20.

Warkentin T, Greinacher A, Gruel Y, Aster R, Chong B . Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost. 2012; 9(12):2498-500. DOI: 10.1111/j.1538-7836.2011.04536.x. View